NAME OF DRUG
Active
Cephalexin monohydrate

Inactive
Capsule 250 mg:
Lactose and magnesium stearate. The capsule shell is gelatin. The dark green cap contains patent blue V Cl42051, quinoline yellow Cl47005 and titanium dioxide (E171). The white opaque body contains titanium dioxide. The black ink contains shellac, ethyl alcohol, isopropyl alcohol, n-butyl alcohol, propylene glycol, purified water, ammonium hydroxide, potassium hydroxide and black iron oxide.

Capsule 500 mg:
Magnesium stearate and cellulose-microcrystalline. The capsule shell also contains gelatin and titanium dioxide.

Suspension:
Saccharin sodium, iron oxide yellow Cl77492, simethicone, citric acid-anhydrous, strawberry, apple, raspberry and tutti frutti artificial flavouring, guar gum, sodium benzoate, and sucrose.

DESCRIPTION
Chemical structure of cephalexin monohydrate

![Chemical structure of cephalexin monohydrate](image)

Chemical name
(6R,7R)-7-[(R)-2-amino-2-phenylacetamido]-3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid monohydrate

Molecular formula
C₁₆H₁₇N₃O₄S·H₂O

Molecular Weight
365.41

CAS
23325-78-2

A semisynthetic cephalosporin antibiotic for oral administration. The nucleus of cephalexin is related to that of other cephalosporin antibiotics. The compound is a zwitterion; i.e. the molecule contains both a basic and an acidic group. The isoelectric point of cephalexin in water is approximately 4.5 to 5. The crystalline form of cephalexin, which is available, is a monohydrate. It is a white or almost white crystalline solid having a bitter taste. Solubility in water is about 1% at room temperature. It is practically insoluble in alcohol and in ether. The cephalosporins differ from penicillins in the structure of the bicyclic ring system. Cephalexin has a d-phenylglycyl group as substituent at the 7-amino position and an unsubstituted methyl group at the 3-position.

ACTIONS
Microbiology
In vitro tests demonstrate that the cephalosporins are bactericidal because they inhibit cell wall synthesis. Cephalexin is active against the following organisms in vitro: β-haemolytic Streptococci, Staphylococci, including coagulase-positive, coagulase-negative, and penicillinase producing strains, Streptococcus (Diplococcus) pneumoniae, Escherichia coli, Proteus mirabilis, Klebsiella sp.

Note: Most strains of Enterococci (Enterococcus faecalis) and a few strains of Staphylococci are resistant to cephalexin. It is not active against most strains of Enterobacter sp., Morganella morganii (formerly Pr. morganii), and Pr. vulgaris.
It has no activity against Pseudomonas or *Acinetobacter calcoaceticus* (formerly Mima and Herellea sp.). When tested by *in vitro* methods, Staphylococci exhibit cross resistance between cephalexin and methicillin type antibiotics.

**Disc susceptibility tests:**
Dilution or diffusion techniques – either quantitative (MIC) or breakpoint, should be used following a regularly updated, recognised and standardised method (e.g. NCCLS). Standardised susceptibility test procedures require the use of laboratory control microorganisms to control the technical aspects of the laboratory procedures.

A report of “Susceptible” indicates that the pathogen is likely to be inhibited if the antimicrobial compound in the blood reaches the concentrations usually achievable. A report of “Intermediate” indicates that the result should be considered equivocal, and if the microorganism is not fully susceptible to alternative, clinically feasible drugs, the test should be repeated. This category implies possible clinical applicability in body sites where the drug is physiologically concentrated or in situations where high dosage of drug can be used. This category also provides a buffer zone, which prevents small-uncontrolled technical factors from causing major discrepancies in interpretation. A report of “Resistant” indicates that the pathogen is not likely to be inhibited if the antimicrobial compound in the blood reaches the concentrations usually achievable; other therapy should be selected.

**Note:** The prevalence of resistance may vary geographically for selected species and local information on resistance is desirable, particularly when treating severe infections.

**Pharmacokinetics**
Cephalexin is acid stable and may be given without regard to meals. It is rapidly absorbed after oral administration. Following a dose of 500 mg, average peak serum levels of approximately 19 microgram/mL were obtained at one hour. Measurable levels were present six hours after administration. Cephalexin is excreted in the urine by glomerular filtration and tubular secretion. Studies have shown that over 90% of the drug is excreted unchanged in the urine within 8 hours. During this period, reported peak urine concentrations following 250 mg, 500 mg and 1 g doses were approximately 1,000, 2,200 and 5,000 microgram/mL, respectively.

**INDICATIONS**
Treatment of the following infections when caused by susceptible strains of the designated microorganisms.

**Respiratory Tract Infections:** Caused by *S. pneumoniae* and group A β-haemolytic Streptococci (penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. Cephalexin is generally effective in the eradication of Streptococci from the nasopharynx; however, substantial data establishing the efficacy of cephalexin in the subsequent prevention of rheumatic fever are not available at present).

**Bacterial Sinusitis:** Caused by Streptococci, *S. pneumoniae* and *S. aureus* (methicillin sensitive only).

**Otitis Media:** Due to *S. pneumoniae*, Staphylococci.

**Skin and Skin Structure Infections:** Caused by Staphylococci and/or Streptococci.

**Genitourinary Tract Infections, including Acute Prostatitis:** Caused by *E. coli*, *P. mirabilis* and Klebsiella sp.

The effectiveness of cephalexin in the treatment of bacterial infections of the brain and spinal column has not been established and cephalexin is not indicated in these conditions.

**Note:** Appropriate culture and susceptibility tests should be initiated prior to and during therapy to determine susceptibility of the causative organism to cephalexin. Renal function studies should be performed when indicated.
CONTRAINDICATIONS
Known allergy to the cephalosporin group of antibiotics or previous experience of a major allergy to penicillin (see PRECAUTIONS).

PRECAUTIONS
Before instituting therapy with cephalexin, every attempt should be made to determine if the patient has had previous hypersensitivity reactions to the cephalosporins, penicillins, or other drugs. This product should be given cautiously to penicillin sensitive patients.

There is some clinical and laboratory evidence of partial cross allergenicity of the penicillins and the cephalosporins. Patients have been reported to have had severe reactions (including anaphylaxis) to both drugs.

Broad spectrum antibiotics should be prescribed with caution in individuals with a history of gastrointestinal disease, particularly colitis. As with other broad spectrum antibiotics, colitis, including rare instances of pseudomembranous colitis, has been reported in conjunction with therapy with cephalexin.

Pseudomembranous colitis has been reported with virtually all broad spectrum antibiotics (including macrolides, semisynthetic penicillins and cephalosporins); therefore, it is important to consider its diagnosis in patients who develop diarrhoea in association with the use of antibiotics. Mild cases of pseudomembranous colitis usually respond to drug discontinuance alone. In moderate to severe cases, appropriate measures should be taken. A toxin produced with Clostridium difficile appears to be the primary cause. The severity of the colitis may range from mild to life-threatening. It is important to consider this diagnosis in patients who develop diarrhoea or colitis in association with antibiotic use (this may occur up to several weeks after cessation of antibiotic therapy). Mild cases usually respond to drug discontinuation alone. However, in moderate to severe cases appropriate therapy with a suitable oral antibacterial agent effective against Cl. difficile should be considered. Drugs that delay peristalsis, e.g. opiates and diphenoxylate with atropine (e.g. Lomotil), may prolong and/or worsen the condition and should not be used.

Patients should be followed carefully so that any side effects or unusual manifestations of drug idiosyncrasy may be detected. If an allergic reaction to cephalexin occurs, the drug should be discontinued and the patient treated with the usual agents (e.g. adrenaline or other pressor amines, antihistamines or corticosteroids).

Prolonged use of cephalexin may result in the overgrowth of non-susceptible organisms. Careful observation of the patient is essential. If superinfection occurs during therapy, appropriate measures should be taken.

Indicated surgical procedures should be performed in conjunction with antibiotic therapy.

Impaired Renal Function
Cephalexin should be administered with caution in the presence of markedly impaired renal function. Careful clinical and laboratory studies should be made because safe dosage may be lower than that usually recommended.

Use in Pregnancy (Category A)
Laboratory experiments with animals and clinical experience show no evidence of teratogenicity with cephalexin, but as with all drugs, cephalexin should be administered with caution during all stages of pregnancy.

Use in Lactation
Cephalexin is excreted in the milk. Caution should be exercised when cephalexin is administered to a breastfeeding woman. Alternative feeding arrangements for the infant should be considered.
INTERACTIONS

Drug Interactions

Probenecid: Probenecid decreases the renal tubular secretion of cephalaxin resulting in increased and prolonged serum concentrations and increased elimination half life and consequently an increased risk of toxicity.

Metformin: In healthy subjects given single 500 mg doses of cephalaxin and metformin, plasma metformin $C_{max}$ and AUC increased by an average of 34% and 24%, respectively, and metformin renal clearance decreased by an average of 14%. The interaction of cephalaxin and metformin following multiple dose administration has not been studied. Administration of a cephalosporin to a metformin-treated patient may result in increased metformin exposure.

Laboratory Tests

Positive direct Coombs’ tests have been reported during treatment with the cephalosporin antibiotics. In haematological studies or in transfusion cross matching procedures when antiglobulin tests are performed on the minor side or in Coombs’ testing of newborn infants whose mothers have received cephalosporin antibiotics before parturition, it should be recognised that a positive Coombs’ test may be due to the drug.

A false positive reaction for glucose in the urine may occur with Benedict’s or Fehling’s solutions or with Clinitest tablets, but not with urine sugar tape (Tes-Tape). The quantitative determination of urinary protein excretion using strong acids is misleading during cephalaxin therapy as precipitation of cephalaxin in the urine may occur.

ADVERSE REACTIONS

Central nervous system
Dizziness, headache, agitation, confusion, hallucinations

Gastrointestinal
Symptoms of pseudomembranous colitis may appear either during or after antibiotic treatment. The most frequent side effect has been diarrhoea, which may rarely be severe enough to warrant cessation of therapy with cephalaxin (see PRECAUTIONS). Nausea and vomiting have been reported rarely. Dyspepsia and abdominal pain have also occurred. As with some penicillins and some other cephalosporins, transient hepatitis and cholestatic jaundice have been reported rarely.

Haematological
Eosinophilia, neutropenia and haemolytic anaemia.

Hepatic
As with some penicillins and some other cephalosporins, transient hepatitis and cholestatic jaundice have been reported rarely. Slight elevations in AST and ALT have also been reported.

Hypersensitivity
Allergic reactions in the form of rash, urticaria, angioedema, and rarely, erythema multiforme, Stevens-Johnson syndrome, or toxic epidermal necrolysis have been observed. These reactions usually subsided upon discontinuation of the drug. Anaphylaxis has also been reported.

Musculoskeletal: fatigue, arthralgia, arthritis and joint disorders.

Renal: reversible interstitial nephritis has been reported rarely.

Urogenital: genital and anal pruritus, genital moniliasis, vaginitis and vaginal discharge.
DOSAGE AND ADMINISTRATION
Administered orally.

Adults
The adult dosage ranges from 1 to 4 g daily in divided doses. The usual adult dose is 250 mg every six hours.

For streptococcal pharyngitis or tonsillitis, mild, uncomplicated urinary tract infections, and skin and skin structure infections, a dosage of 500 mg may be administered every twelve hours.

For more severe infections or those caused by less susceptible organisms, larger doses may be needed. If daily doses of cephalalexin greater than 4 g are required, parenteral cephalosporins, in appropriate doses, should be considered.

Twice daily dosing is not recommended when doses larger than 1 g daily are administered.

Children
The usual recommended daily dosage for children is 25 to 50 mg/kg in divided doses. For streptococcal pharyngitis in patients over 1 year of age, tonsillitis, mild, uncomplicated urinary tract infection, and skin and skin structure infections, the total daily dose may be divided and administered every twelve hours.

<table>
<thead>
<tr>
<th>Part A: Four times daily dosage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Child's weight</td>
</tr>
<tr>
<td>----------------</td>
</tr>
<tr>
<td>10 kg</td>
</tr>
<tr>
<td>20 kg</td>
</tr>
<tr>
<td>40 kg</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Part B: Twice daily dosage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Child's weight</td>
</tr>
<tr>
<td>----------------</td>
</tr>
<tr>
<td>10 kg</td>
</tr>
<tr>
<td>20 kg</td>
</tr>
<tr>
<td>40 kg</td>
</tr>
</tbody>
</table>

In severe infections, the dosage may be doubled. In the therapy of otitis media, clinical studies have shown that a dosage of 75 to 100 mg/kg/day in four divided doses is recommended.

In the treatment of β-haemolytic streptococcal infections, a therapeutic dosage of cephalalexin should be administered for at least 10 days.

Impaired renal function: (see PRECAUTIONS)

OVERDOSAGE
There is no definite experience of poisoning or severe overdosage with cephalalexin. However, clinical features of overdosage may be similar to those seen with other cephalosporins and penicillins, ie. convulsions, hallucinations, hyperreflexia, electrolyte imbalance, gastrointestinal disturbances and haematuria.

In the event of severe overdosage, general supportive care is recommended including close clinical and laboratory monitoring of haematological, renal, hepatic functions and coagulation status until the patient is stable.

Forced diuresis, peritoneal dialysis, haemodialysis or charcoal haemoperfusion have not been established as beneficial for an overdose of cephalalexin.

Contact the Poison Information Centre on 13 11 26 (Australia) for advice on the management of overdosage.
STORAGE

Capsule
Store below 25°C. Protect from moisture.

Powder for Oral Suspension
Before Mixing: Store below 25°C. Protect from light and moisture.
After Mixing: Store at 2 to 8°C. (Refrigerate. Do not freeze) and discard unused portion 14 days after reconstitution.

PRESENTATION
Capsules 250 mg - Dark green/white, imprinted with two parallel black lines in 20’s
Capsules 500 mg - White opaque in colour, containing a white to yellowish powder in 20’s

Powder for Oral Suspension
Cephalexin Powder for Oral Suspension contains cephalexin (as monohydrate) equivalent to 125mg/5mL or 250mg/5mL of cephalexin anhydrous. The suspension is orange-yellow in colour with a fruity flavour. It is available in 100 mL.

NAME AND ADDRESS OF SPONSOR
GenRx Pty Ltd
ABN 52 096 916 148
Suite 2B, Level 3, Building A
11 Talavera Road,
North Ryde NSW 2113
Australia

DISTRIBUTOR
Symbion Pharmacy Services Pty Ltd
ABN 25 000 875 034
48-58 Overseas Drive
Noble Park North VIC 3174
Australia

Chemmart is a registered trade mark of Symbion Pharmacy Services Pty Ltd

Date of TGA approval: 21 January 2004
Date of most recent amendment: 23 June 2006